Gilead Sciences (GILD) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Gilead’s HIV sector, populated by dominant HIV treatment Biktarvy and PrEP Descovy, contributed $5.1 billion to the company’s total quarterly sales haul of $7.5 billion, reflecting growth of 7 ...

The press release, slides, and supplementary data are available on the investors section of our website at gilead.com. The speakers on today’s call will be our Chairman and Chief Executive ...

Gilead Sciences (NASDAQ:GILD) will release its quarterly earnings report on Wednesday, 2024-11-06. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Gilead ...

With Gilead Sciences sprinting to a likely approval next year for its long-acting pre-exposure prophylaxis (PrEP) drug for HIV, the California company has a chance to one-up GSK. While the British ...

Gilead Sciences (GILD) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.

Nov 6 (Reuters) - Gilead Sciences (GILD.O), opens new tab reported third-quarter financial results that handily beat Wall Street expectations on Wednesday as sales climbed 7%, leading the ...

In a report released yesterday, Tyler Van Buren from TD Cowen maintained a Buy rating on Gilead Sciences (GILD – Research Report), with a price target of $95.00. Tyler Van Buren’s rating is ...